webinar register page

Bedaquiline resistance and the BPaLM regimen for RR-TB treatment – knowledge gaps and translation from guideline to practice
Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global public health, with half a millions of RR-TB cases annually worldwide. Endorsement of WHO for the new BPaL(M) regimens based on the promising results of the TB-PRACTECAL trial brings new hope for RR-TB patients. This move underlines again the indispensability of bedaquiline (BDQ) for the treatment of RR-TB, yet the emergence of BDQ resistance and the current lack of accurate susceptibility tests for BDQ is posing a threat.
In this webinar, we will address several important questions. What did the PRACTECAL trial show? What is the burden of bedaquiline resistance? What are problems in diagnosing BDQ resistance? How can we overcome these challenges and use BDQ more effectively?

Jun 24, 2022 12:00 PM in Brussels

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Webinars webinars - itg.be.